Copeland Clinical Ai (C2-Ai) was originally launched as Crab Clinical Informatics in 2008 by Stephen Mackenney, with the help of a long-standing colleague, Graham Copeland, the architect of the POSSUM surgical audit system, a world-renowned methodology for assessing clinical performance against the expected outcome for surgical patients.
With over 30 years of research, Copeland Clinical Ai, Inc. has developed, tested, and proven unique clinical Artificial Intelligence (AI)-backed systems that help hospitals and health systems worldwide demonstrably reduce avoidable harm, mortality, and cost. By accurately risk adjusting for each patient, Copeland Clinical Ai systems provide hospitals with the ability to see up to 90% more harm than their current systems, identify which hospitals and specialists are doing well, where hospitals have issues with mortality and complications, the causes and economic impact, and how to resolve the issues and avoid future harm.
The approach is proven to work across different geographies and is being used in hospitals globally, as well as by regulatory authorities such as the UK’s Care Quality Commission. Unlike other solutions, the approach is individualized, with ‘made-to-measure’ results for every patient, accurately adjusted for physiological characteristics and multiple triggers. The risk of complications is patient-specific and can be used to improve care, avoid harm, and demonstrably reduce associated costs.
C2-Ai has offices in St. Petersburg, Florida, and Cambridge, United Kingdom.
Demonstrably helping reduce avoidable variation, mortality, and harm in hospitals globally.
Considering patients as individuals and helping personalize their treatment and management of risks and complications.
Helping hospitals avoid risks, reduce wasted expenditure, and save on negligence costs through timely identification and resolution of issues.